Evidence map›Paper›PMID 41889021›Full record

ArticleCancer biology & medicine2026

Enhancing FIT-based colorectal cancer screening through risk prediction: a comparative evaluation of 17 models in a large Chinese cohort.

Le Wang, Weimiao Wu, Bin Liu, Chen Zhu, Yumeng Ding, Yi Zhou, Weiwei Chen, Lijuan Dai, Xueni Chen, Yuefan Shen and 7 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Le Wang *Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Weimiao Wu *Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Bin Liu *Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Chen ZhuDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Yumeng DingDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Yi ZhouDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Weiwei ChenDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing 211166, China.
Lijuan DaiDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing 211166, China.
Xueni ChenDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing 211166, China.
Yuefan ShenDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing 211166, China.
Tingting PanDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Xiaohui SunDepartment of Epidemiology, School of Public Health, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Huizhang LiDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Dong HangDepartment of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing 211166, China.
Yingying MaoDepartment of Epidemiology, School of Public Health, Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID 0000-0003-3644-9160
Partha BasuEarly Detection, Prevention & Infections Branch, International Agency for Research on Cancer (WHO), Lyon 69007, France.ORCID 0000-0003-0124-4050
Lingbin DuDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.ORCID 0000-0002-1992-7784

Funding

Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0520100Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0520103Postdoctoral Science Foundation of Zhejiang Province ZJ2024074Science and Technology Program for Disease Prevention and Control of Zhejiang Province 2025JK018Zhejiang Provincial Medical and Health Science and Technology Plan 2025KY677Zhejiang Provincial Natural Science Foundation of China LQN25G030004Zhejiang Provincial Natural Science Foundation of China LTGY23H260004
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41889021
PMCPMC13449708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.